The Biology of Retinopathy of Prematurity: How Knowledge of Pathogenesis Guides Treatment

Clinics in Perinatology

Volumn 40, Issue 2, 2013, Pages 201-214

  Smith, Lois E ^a   Hard, Anna Lena ^b   Hellström, Ann ^b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b QUEEN SILVIA CHILDREN'S HOSPITAL   (Sweden)

Author keywords

Erythropoietin; IGF 1; Omega 3 polyunsaturated fatty acids; Oxygen; Postnatal weight gain

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; BEVACIZUMAB; ERYTHROPOIETIN; GROWTH FACTOR; OMEGA 3 FATTY ACID; OXYGEN; POLYUNSATURATED FATTY ACID; RANIBIZUMAB; RECOMBINANT ERYTHROPOIETIN; SMALL INTERFERING RNA; SOMATOMEDIN C; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR;

ABSENCE OF SIDE EFFECTS; ANEMIA; ANGIOGENESIS; BIRTH WEIGHT; DIABETIC MACULAR EDEMA; DISEASE COURSE; HUMAN; HYPEROXIA; HYPOXIA; LASER SURGERY; MALNUTRITION; MOLECULAR BIOLOGY; MOLECULAR MECHANICS; MOLECULAR PATHOLOGY; NONHUMAN; NUTRITION; PATHOGENESIS; POSTNATAL GROWTH; PREDICTION; PREMATURE LABOR; PREMATURITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA BLOOD VESSEL; RETINA DEVELOPMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; RETROLENTAL FIBROPLASIA; REVIEW; WEIGHT GAIN;

ERYTHROPOIETIN; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; INSULIN-LIKE GROWTH FACTOR I; OXYGEN; RETINA; RETINOPATHY OF PREMATURITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84878204556     PISSN: 00955108     EISSN: 15579840     Source Type: Journal    
DOI: 10.1016/j.clp.2013.02.002     Document Type: Review

References (79)

1. Wikstrand M.H., Hard A.L., Niklasson A., et al. Maternal and neonatal factors associated with poor early weight gain and later retinopathy of prematurity. Acta Paediatr 2011, 100(12):1528-1533.
2. Singer D., Muhlfeld C. Perinatal adaptation in mammals: the impact of metabolic rate. Comp Biochem Physiol A Mol Integr Physiol 2007, 148(4):780-784.
3. Lofqvist C., Andersson E., Sigurdsson J., et al. Longitudinal postnatal weight and insulin-like growth factor I measurements in the prediction of retinopathy of prematurity. Arch Ophthalmol 2006, 124(12):1711-1718.
4. Hellstrom A., Hard A.L., Engstrom E., et al. Early weight gain predicts retinopathy in preterm infants: new, simple, efficient approach to screening. Pediatrics 2009, 123(4):e638-e645.
5. Lofqvist C., Hansen-Pupp I., Andersson E., et al. Validation of a new retinopathy of prematurity screening method monitoring longitudinal postnatal weight and insulinlike growth factor I. Arch Ophthalmol 2009, 127(5):622-627.
6. Terry T.L. Extreme prematurity and fibroblastic overgrowth of persistent vascular sheath behind each crystalline lens. Am J Ophthalmol 1942, 25:203-204.
7. Patz A., Hoeck L.E., De La Cruz E. Studies on the effect of high oxygen administration in retrolental fibroplasia. I. Nursery observations. Am J Ophthalmol 1952, 35(9):1248-1253.
8. Ashton N., Ward B., Serpell G. Effect of oxygen on developing retinal vessels with particular reference to the problem of retrolental fibroplasia. Br J Ophthalmol 1954, 38(7):397-432.
9. Bolton D.P., Cross K.W. Further observations on cost of preventing retrolental fibroplasia. Lancet 1974, 1(7855):445-448.
10. Stenson B., Brocklehurst P., Tarnow-Mordi W. Increased 36-week survival with high oxygen saturation target in extremely preterm infants. N Engl J Med 2011, 364(17):1680-1682.
11. Of Prematurity (STOP-ROP), a randomized, controlled trial. I: primary outcomes. Pediatrics 2000, 105(2):295-310.
12. Chen M.L., Guo L., Smith L.E., et al. High or low oxygen saturation and severe retinopathy of prematurity: a meta-analysis. Pediatrics 2010, 125(6):e1483-e1492.
13. Gilbert C., Muhit M. Twenty years of childhood blindness: what have we learnt?. Community Eye Health 2008, 21(67):46-47.
14. Gilbert C., Foster A. Childhood blindness in the context of VISION 2020-the right to sight. Bull World Health Organ 2001, 79(3):227-232.
15. Gilbert C., Fielder A., Gordillo L., et al. Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implications for screening programs. Pediatrics 2005, 115(5):e518-e525.
16. Roth A.M. Retinal vascular development in premature infants. Am J Ophthalmol 1977, 84(5):636-640.
17. Michaelson IC. The mode of development of the vascular system of the retina, with some observations on its significance for certain retinal diseases. Trans Ophthalmol Soc UK 68:137-80.
18. Chan-Ling T., McLeod D.S., Hughes S., et al. Astrocyte-endothelial cell relationships during human retinal vascular development. Invest Ophthalmol Vis Sci 2004, 45(6):2020-2032.
19. Hughes S., Yang H., Chan-Ling T. Vascularization of the human fetal retina: roles of vasculogenesis and angiogenesis. Invest Ophthalmol Vis Sci 2000, 41(5):1217-1228.
20. Chan-Ling T., Gock B., Stone J. The effect of oxygen on vasoformative cell division. Evidence that 'physiological hypoxia' is the stimulus for normal retinal vasculogenesis. Invest Ophthalmol Vis Sci 1995, 36(7):1201-1214.
21. Pierce E.A., Avery R.L., Foley E.D., et al. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci U S A 1995, 92(3):905-909.
22. Pierce E.A., Foley E.D., Smith L.E. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol 1996, 114(10):1219-1228.
23. Madan A., Penn J.S. Animal models of oxygen-induced retinopathy. Front Biosci 2003, 8:d1030-d1043.
24. Smith L.E. Through the eyes of a child: understanding retinopathy through ROP the Friedenwald lecture. Invest Ophthalmol Vis Sci 2008, 49(12):5177-5182.
25. Good W.V., Hardy R.J., Dobson V., et al. The incidence and course of retinopathy of prematurity: findings from the early treatment for retinopathy of prematurity study. Pediatrics 2005, 116(1):15-23.
26. Austeng D., Kallen K.B., Hellstrom A., et al. Natural history of retinopathy of prematurity in infants born before 27 weeks' gestation in Sweden. Arch Ophthalmol 2010, 128(10):1289-1294.
27. Shah P.K., Narendran V., Kalpana N. Aggressive posterior retinopathy of prematurity in large preterm babies in South India. Arch Dis Child Fetal Neonatal Ed 2012, 97(5):F371-F375.
28. Campbell K. Intensive oxygen therapy as a possible cause of retrolental fibroplasia; a clinical approach. Med J Aust 1951, 2(2):48-50.
29. Chen J., Smith L.E. Retinopathy of prematurity. Angiogenesis 2007, 10(2):133-140.
30. Smith L.E., Wesolowski E., McLellan A., et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 1994, 35(1):101-111.
31. Shweiki D., Itin A., Soffer D., et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992, 359(6398):843-845.
32. Leung D.W., Cachianes G., Kuang W.J., et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246(4935):1306-1309.
33. Shih S.C., Ju M., Liu N., et al. Selective stimulation of VEGFR-1 prevents oxygen-induced retinal vascular degeneration in retinopathy of prematurity. J Clin Invest 2003, 112(1):50-57.
34. Aiello L.P., Pierce E.A., Foley E.D., et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A 1995, 92(23):10457-10461.
35. Robinson G.S., Pierce E.A., Rook S.L., et al. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci U S A 1996, 93(10):4851-4856.
36. Stone J., Itin A., Alon T., et al. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci 1995, 15(7 Pt 1):4738-4747.
37. Stone J., Chan-Ling T., Pe'er J., et al. Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity. Invest Ophthalmol Vis Sci 1996, 37(2):290-299.
38. Jiang J., Xia X.B., Xu H.Z., et al. Inhibition of retinal neovascularization by gene transfer of small interfering RNA targeting HIF-1alpha and VEGF. J Cell Physiol 2009, 218(1):66-74.
39. Sato T., Wada K., Arahori H., et al. Serum Concentrations of Bevacizumab (Avastin) and Vascular Endothelial Growth Factor in Infants With Retinopathy of Prematurity. Am J Ophthalmol 2011, 153(2):327-333.e1.
40. Shah P.K., Narendran V., Tawansy K.A., et al. Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity. Indian J Ophthalmol 2007, 55(1):75-76.
41. Kong L., Mintz-Hittner H.A., Penland R.L., et al. Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study. Arch Ophthalmol 2008, 126(8):1161-1163.
42. Mintz-Hittner H.A., Kuffel R.R. Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina 2008, 28(6):831-838.
43. Weidemann A., Krohne T.U., Aguilar E., et al. Astrocyte hypoxic response is essential for pathological but not developmental angiogenesis of the retina. Glia 2010, 58(10):1177-1185.
44. Shalev B., Farr A.K., Repka M.X. Randomized comparison of diode laser photocoagulation versus cryotherapy for threshold retinopathy of prematurity: seven-year outcome. Am J Ophthalmol 2001, 132(1):76-80.
45. Multicenter trial of cryotherapy for retinopathy of prematurity: preliminary results. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Pediatrics 1988, 81(5):697-706.
46. Tasman W. Ten-year follow-up from the CRYO-ROP study. Arch Ophthalmol 2001, 119(8):1200-1201.
47. Young T.L., Anthony D.C., Pierce E., et al. Histopathology and vascular endothelial growth factor in untreated and diode laser-treated retinopathy of prematurity. J AAPOS 1997, 1(2):105-110.
48. Stefansson E. The therapeutic effects of retinal laser treatment and vitrectomy. A theory based on oxygen and vascular physiology. Acta Ophthalmol Scand 2001, 79(5):435-440.
49. Jaquet K., Krause K., Tawakol-Khodai M., et al. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res 2002, 64(2):326-333.
50. Ribatti D., Vacca A., Roccaro A.M., et al. Erythropoietin as an angiogenic factor. Eur J Clin Invest 2003, 33(10):891-896.
51. Chen J., Connor K.M., Aderman C.M., et al. Erythropoietin deficiency decreases vascular stability in mice. J Clin Invest 2008, 118(2):526-533.
52. Smith S.B., Duplantier J., Dun Y., et al. In vivo protection against retinal neurodegeneration by sigma receptor 1 ligand (+)-pentazocine. Invest Ophthalmol Vis Sci 2008, 49(9):4154-4161.
53. Chen J., Smith L.E. A double-edged sword: erythropoietin eyed in retinopathy of prematurity. J AAPOS 2008, 12(3):221-222.
54. Manzoni P., Maestri A., Gomirato G., et al. Erythropoietin as a retinal angiogenic factor. N Engl J Med 2005, 353(20):2190-2191. [author reply: 1].
55. Chen J., Connor K.M., Aderman C.M., et al. Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy. Invest Ophthalmol Vis Sci 2009, 50(3):1329-1335.
56. Suk K.K., Dunbar J.A., Liu A., et al. Human recombinant erythropoietin and the incidence of retinopathy of prematurity: a multiple regression model. J AAPOS 2008, 12(3):233-238.
57. Aher S.M., Ohlsson A. Early versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2006, (3). CD004865.
58. Gyllensten L.J., Hellstrom B.E. Experimental approach to the pathogenesis of retrolental fibroplasia. I. Changes of the eye induced by exposure of newborn mice to concentrated oxygen. Acta Paediatr Suppl 1954, 43(100):131-148.
59. Smith L.E., Kopchick J.J., Chen W., et al. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 1997, 276(5319):1706-1709.
60. Hellstrom A., Perruzzi C., Ju M., et al. Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci U S A 2001, 98(10):5804-5808.
61. Langford K., Nicolaides K., Miell J.P. Maternal and fetal insulin-like growth factors and their binding proteins in the second and third trimesters of human pregnancy. Hum Reprod 1998, 13(5):1389-1393.
62. Ong K.K., Langkamp M., Ranke M.B., et al. Insulin-like growth factor I concentrations in infancy predict differential gains in body length and adiposity: the Cambridge Baby Growth Study. Am J Clin Nutr 2009, 90(1):156-161.
63. Fowden A.L. The insulin-like growth factors and feto-placental growth. Placenta 2003, 24(8-9):803-812.
64. Lutty G.A., Chan-Ling T., Phelps D.L., et al. Proceedings of the Third International Symposium on Retinopathy of Prematurity: an update on ROP from the lab to the nursery (November 2003, Anaheim, California). Mol Vis 2006, 12:532-580.
65. Lineham J.D., Smith R.M., Dahlenburg G.W., et al. Circulating insulin-like growth factor I levels in newborn premature and full-term infants followed longitudinally. Early Hum Dev 1986, 13(1):37-46.
66. Hellstrom A., Carlsson B., Niklasson A., et al. IGF-I is critical for normal vascularization of the human retina. J Clin Endocrinol Metab 2002, 87(7):3413-3416.
67. Stahl A., Chen J., Sapieha P., et al. Postnatal weight gain modifies severity and functional outcome of oxygen-induced proliferative retinopathy. Am J Pathol 2010, 177(6):2715-2723.
68. Smith L.E., Shen W., Perruzzi C., et al. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med 1999, 5(12):1390-1395.
69. Lofqvist C., Chen J., Connor K.M., et al. IGFBP3 suppresses retinopathy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth. Proc Natl Acad Sci U S A 2007, 104(25):10589-10594.
70. Wu C., Vanderveen D.K., Hellstrom A., et al. Longitudinal postnatal weight measurements for the prediction of retinopathy of prematurity. Arch Ophthalmol 2010, 128(4):443-447.
71. Hard A.L., Lofqvist C., Fortes Filho J.B., et al. Predicting proliferative retinopathy in a Brazilian population of preterm infants with the screening algorithm WINROP. Arch Ophthalmol 2010, 128(11):1432-1436.
72. Fluckiger S., Bucher H.U., Hellstrom A., et al. The early postnatal weight gain as a predictor of retinopathy of prematurity. Klin Monbl Augenheilkd 2011, 228(4):306-310. [in German].
73. Wu C., Lofqvist C., Smith L.E., et al. Importance of early postnatal weight gain for normal retinal angiogenesis in very preterm infants: a multicenter study analyzing weight velocity deviations for the prediction of retinopathy of prematurity. Arch Ophthalmol 2012, 130(8):992-999.
74. Zepeda-Romero L.C., Hard A.L., Gomez-Ruiz L.M., et al. Prediction of retinopathy of prematurity using the screening algorithm WINROP in a Mexican population of preterm infants. Arch Ophthalmol 2012, 130(6):720-723.
75. Vanhaesebrouck S., Daniels H., Moons L., et al. Oxygen-induced retinopathy in mice: amplification by neonatal IGF-I deficit and attenuation by IGF-I administration. Pediatr Res 2009, 65(3):307-310.
76. Binenbaum G., Ying G.S., Quinn G.E., et al. A clinical prediction model to stratify retinopathy of prematurity risk using postnatal weight gain. Pediatrics 2011, 127(3):e607-e614.
77. Eckert G.U., Fortes Filho J.B., Maia M., et al. A predictive score for retinopathy of prematurity in very low birth weight preterm infants. Eye (Lond) 2012, 26(3):400-406.
78. Connor K.M., SanGiovanni J.P., Lofqvist C., et al. Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med 2007, 13(7):868-873.
79. Sapieha P., Stahl A., Chen J., et al. 5-Lipoxygenase Metabolite 4-HDHA is a mediator of the Antiangiogenic effect of {omega}-3 polyunsaturated fatty acids. Sci Transl Med 2011, 3(69):69ra12.